Funder: Foundation for Women's Cancer
Due Dates: October 7, 2026 (LOI) | December 9, 2026 (Full proposal)
Funding Amounts: $50,000 for one year
Summary: Supports innovative research on therapeutic resistance and improved treatment for high-grade endometrial cancer.
Key Information: Research must occur at a U.S. institution; non-SGO members need a documented SGO co-investigator or sponsor.
Description
The Laughlin Family Foundation supports this research grant through the Foundation for Women’s Cancer (FWC), within its 2026–2027 Endometrial/Uterine Cancer Grants category. The award funds innovative research advancing treatment of high-grade endometrial cancer, particularly work addressing therapeutic resistance. It is the Laughlin Family Foundation’s fourth FWC research grant focused on high-grade uterine cancer.
Research may examine hormonal or endocrine resistance, immune escape, lineage plasticity, tumor-microenvironment interactions, the microbiome’s role in inflammation and treatment response, or biomarkers predicting responsiveness to current or emerging therapies. Priority goes to projects using cutting-edge technologies and translational approaches to identify actionable targets and accelerate therapeutic development. The goal is more durable, personalized care for patients with aggressive endometrial cancers.
